A Slovakian couple is embarking on a desperate race against time too secure a potentially life-altering gene therapy for their two-year-old son,Vilko,recently diagnosed with Duchenne muscular dystrophy. teh rare genetic disorder progressively weakens muscles, and while there is no current cure, emerging gene therapies offer a glimmer of hope. richard and Zuzana Olexa are striving to raise €4 million to access this treatment, a sum beyond the reach of most families and currently unavailable within SlovakiaS healthcare system. Their public appeal highlights not only a personal struggle, but also a growing need for wider access to innovative, though costly, treatments for rare diseases.
A Slovakian couple is racing against time to raise €4 million (approximately $4.3 million USD) for a potentially life-saving gene therapy for their two-year-old son, Vilko, who has been diagnosed with Duchenne muscular dystrophy, a rare and progressive genetic disorder.
Richard and Zuzana Olexa learned of Vilko’s condition after doctors initially dismissed their concerns about his unusually large calf muscles as typical infant development. “They told us they weren’t happy we found out about his illness so early as parents, because we would suffer for longer,” Richard Olexa said, recalling the day they received the diagnosis.
Following the diagnosis, the couple embarked on an intensive search for information, researching the rapidly progressing disease – which often leads to fatality before adulthood – and exploring potential treatments. Richard Olexa purchased medical textbooks and delved into the science behind the condition, hoping to find a path forward.
His research led him to a conference in Dallas, Texas, where leading scientists and neurologists were gathering. Olexa successfully petitioned the organizers to allow him to attend, and traveled to the U.S. to speak with experts, including Nicolas Wein, a renowned specialist in gene therapy.
Wein later invited Olexa to his home in Nantes, France, unaware that the determined visitor was the father of a child with Duchenne muscular dystrophy. The molecular biologist pledged to help the family, but securing the necessary gene therapy for Vilko requires substantial funding.
Richard and Zuzana Olexa have launched a public appeal to raise the €4 million needed for Vilko’s treatment, hoping to not only save their son’s life but also to assist other Slovakian patients with severe neurodegenerative diseases. Their fundraising campaign is available at this link.
The couple’s journey to diagnosis began with Zuzana Olexa’s persistent questioning of medical professionals regarding Vilko’s physical development. “From the first day in the maternity ward, she asked why Vilko had such large calves,” Richard Olexa explained. “They were disproportionately large compared to his body, and compared to his older brother’s calves at birth. She was told it was normal, that the baby was just retaining water, and that the swelling would subside.”
Despite the assurances, Zuzana Olexa remained unconvinced. “She wasn’t completely satisfied with that answer, but at that moment, we had no choice but to believe it,” Richard Olexa said. “My father and brother have very strong legs, so in combination with the possibility of genetics, we calmed down and hoped everything was okay.”
As Vilko grew, the Olexas noticed he wasn’t reaching developmental milestones at the same pace as his older brother. He also experienced prolonged respiratory illnesses, often requiring inhalers and struggling to recover. Concerned about potentially exposing Vilko to further infections, they temporarily withdrew their older son from daycare.
While doctors acknowledged Vilko’s difficulties, they didn’t initially suspect a serious underlying condition. “Naturally, some children cope with illnesses more easily than others,” Richard Olexa said. “I’m not looking to place blame.”
“That’s precisely the insidious nature of Duchenne muscular dystrophy,” he continued. “Often, you don’t find out something is wrong until the symptoms are so severe they impact the patient’s daily life – your child’s life.”
Zuzana Olexa sought guidance from numerous physiotherapists in Košice, hoping to understand the reasons for Vilko’s developmental delays. They were repeatedly told he was a healthy child with a slight delay.
The breakthrough came after Vilko fell from a seated position and struck his head, followed by vomiting an hour later. A visit to the doctor led to tests, and Zuzana Olexa again raised her concerns about Vilko’s developmental progress.
Although the doctor initially attributed the delays to minor setbacks, they ordered baseline metabolic tests. Those results were normal, but a simple test measuring muscle enzyme levels revealed a concerning result: Vilko’s levels were more than one hundred times higher than normal.
“Yesterday marked exactly one year since I received those results,” Richard Olexa said. “When I went to the doctor’s office a year ago, I had no idea why I was there. We had been searching for something online, but we never thought it could be something so serious. I had never even heard of Duchenne muscular dystrophy before. The doctor told me there was a strong likelihood it could be a very serious diagnosis, probably muscular dystrophy.”
“I didn’t know what that meant at the time, and even from her explanation, I didn’t fully grasp the severity of the situation. I sat in the car with the report and started googling,” he said.
“That day is something we will remember for the rest of our lives.”
